ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-23P5573
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Drugs for Duchenne Muscular Dystrophy DMD Market Size Status and Forecast 2021 2027
BUY CHAPTERS

Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Research Report 2025

Code: QYRE-Auto-23P5573
Report
July 2025
Pages:71
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sarepta Therapeutics
PTC Therapeutics
Pfizer Inc
Bristol–Myers Squibb
Italfarmaco S.p.A.
Santhera Pharmaceuticals
WaVe life Science

Drugs for Duchenne Muscular Dystrophy (DMD) Market Size

The global market for Drugs for Duchenne Muscular Dystrophy (DMD) was valued at US$ 226 million in the year 2024 and is projected to reach a revised size of US$ 470 million by 2031, growing at a CAGR of 11.2% during the forecast period.

Drugs for Duchenne Muscular Dystrophy (DMD) Market

Drugs for Duchenne Muscular Dystrophy (DMD) Market

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Duchenne Muscular Dystrophy (DMD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Duchenne Muscular Dystrophy (DMD).
The Drugs for Duchenne Muscular Dystrophy (DMD) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs for Duchenne Muscular Dystrophy (DMD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Duchenne Muscular Dystrophy (DMD) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Drugs for Duchenne Muscular Dystrophy (DMD) Market Report

Report Metric Details
Report Name Drugs for Duchenne Muscular Dystrophy (DMD) Market
Accounted market size in year US$ 226 million
Forecasted market size in 2031 US$ 470 million
CAGR 11.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospitals
  • Clinics
  • Home Care
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals, WaVe life Science
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Drugs for Duchenne Muscular Dystrophy (DMD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Drugs for Duchenne Muscular Dystrophy (DMD) Market growing?

Ans: The Drugs for Duchenne Muscular Dystrophy (DMD) Market witnessing a CAGR of 11.2% during the forecast period 2025-2031.

What is the Drugs for Duchenne Muscular Dystrophy (DMD) Market size in 2031?

Ans: The Drugs for Duchenne Muscular Dystrophy (DMD) Market size in 2031 will be US$ 470 million.

Who are the main players in the Drugs for Duchenne Muscular Dystrophy (DMD) Market report?

Ans: The main players in the Drugs for Duchenne Muscular Dystrophy (DMD) Market are Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals, WaVe life Science

What are the Application segmentation covered in the Drugs for Duchenne Muscular Dystrophy (DMD) Market report?

Ans: The Applications covered in the Drugs for Duchenne Muscular Dystrophy (DMD) Market report are Hospitals, Clinics, Home Care

What are the Type segmentation covered in the Drugs for Duchenne Muscular Dystrophy (DMD) Market report?

Ans: The Types covered in the Drugs for Duchenne Muscular Dystrophy (DMD) Market report are Eteplirsen, Deflazacort, Ataluren

Recommended Reports

Neuromuscular Disorders

Genetic Disease Treatment

Musculoskeletal Therapies

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Eteplirsen
1.2.3 Deflazacort
1.2.4 Ataluren
1.3 Market by Application
1.3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Perspective (2020-2031)
2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Growth Trends by Region
2.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Region (2020-2025)
2.2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Region (2026-2031)
2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Dynamics
2.3.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends
2.3.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers
2.3.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
2.3.4 Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Revenue
3.1.1 Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Revenue (2020-2025)
3.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Players (2020-2025)
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue
3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Ratio
3.4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2024
3.5 Global Key Players of Drugs for Duchenne Muscular Dystrophy (DMD) Head office and Area Served
3.6 Global Key Players of Drugs for Duchenne Muscular Dystrophy (DMD), Product and Application
3.7 Global Key Players of Drugs for Duchenne Muscular Dystrophy (DMD), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Duchenne Muscular Dystrophy (DMD) Breakdown Data by Type
4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Type (2020-2025)
4.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Type (2026-2031)
5 Drugs for Duchenne Muscular Dystrophy (DMD) Breakdown Data by Application
5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Application (2020-2025)
5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2020-2031)
6.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025)
6.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2020-2031)
7.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025)
7.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2020-2031)
8.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025)
8.4 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2020-2031)
9.2 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025)
9.4 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2020-2031)
10.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025)
10.4 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.1.4 Sarepta Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
11.1.5 Sarepta Therapeutics Recent Development
11.2 PTC Therapeutics
11.2.1 PTC Therapeutics Company Details
11.2.2 PTC Therapeutics Business Overview
11.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.2.4 PTC Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
11.2.5 PTC Therapeutics Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.3.4 Pfizer Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
11.3.5 Pfizer Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.4.4 Bristol-Myers Squibb Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Italfarmaco
11.5.1 Italfarmaco Company Details
11.5.2 Italfarmaco Business Overview
11.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.5.4 Italfarmaco Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
11.5.5 Italfarmaco Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Details
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
11.6.5 Santhera Pharmaceuticals Recent Development
11.7 WaVe life Science
11.7.1 WaVe life Science Company Details
11.7.2 WaVe life Science Business Overview
11.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.7.4 WaVe life Science Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
11.7.5 WaVe life Science Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Sarepta Therapeutics
PTC Therapeutics
Pfizer Inc
Bristol–Myers Squibb
Italfarmaco S.p.A.
Santhera Pharmaceuticals
WaVe life Science
List of Tables
 Table 1. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Eteplirsen
 Table 3. Key Players of Deflazacort
 Table 4. Key Players of Ataluren
 Table 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2020-2025)
 Table 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2026-2031)
 Table 11. Drugs for Duchenne Muscular Dystrophy (DMD) Market Trends
 Table 12. Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers
 Table 13. Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
 Table 14. Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints
 Table 15. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Players (2020-2025)
 Table 17. Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2024)
 Table 18. Ranking of Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Drugs for Duchenne Muscular Dystrophy (DMD), Headquarters and Area Served
 Table 21. Global Key Players of Drugs for Duchenne Muscular Dystrophy (DMD), Product and Application
 Table 22. Global Key Players of Drugs for Duchenne Muscular Dystrophy (DMD), Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2020-2025)
 Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2026-2031)
 Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2020-2025)
 Table 30. Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2026-2031)
 Table 32. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Sarepta Therapeutics Company Details
 Table 48. Sarepta Therapeutics Business Overview
 Table 49. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product
 Table 50. Sarepta Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025) & (US$ Million)
 Table 51. Sarepta Therapeutics Recent Development
 Table 52. PTC Therapeutics Company Details
 Table 53. PTC Therapeutics Business Overview
 Table 54. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product
 Table 55. PTC Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025) & (US$ Million)
 Table 56. PTC Therapeutics Recent Development
 Table 57. Pfizer Company Details
 Table 58. Pfizer Business Overview
 Table 59. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product
 Table 60. Pfizer Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025) & (US$ Million)
 Table 61. Pfizer Recent Development
 Table 62. Bristol-Myers Squibb Company Details
 Table 63. Bristol-Myers Squibb Business Overview
 Table 64. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product
 Table 65. Bristol-Myers Squibb Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025) & (US$ Million)
 Table 66. Bristol-Myers Squibb Recent Development
 Table 67. Italfarmaco Company Details
 Table 68. Italfarmaco Business Overview
 Table 69. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product
 Table 70. Italfarmaco Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025) & (US$ Million)
 Table 71. Italfarmaco Recent Development
 Table 72. Santhera Pharmaceuticals Company Details
 Table 73. Santhera Pharmaceuticals Business Overview
 Table 74. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product
 Table 75. Santhera Pharmaceuticals Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025) & (US$ Million)
 Table 76. Santhera Pharmaceuticals Recent Development
 Table 77. WaVe life Science Company Details
 Table 78. WaVe life Science Business Overview
 Table 79. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product
 Table 80. WaVe life Science Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025) & (US$ Million)
 Table 81. WaVe life Science Recent Development
 Table 82. Research Programs/Design for This Report
 Table 83. Key Data Information from Secondary Sources
 Table 84. Key Data Information from Primary Sources
 Table 85. Authors List of This Report


List of Figures
 Figure 1. Drugs for Duchenne Muscular Dystrophy (DMD) Picture
 Figure 2. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type: 2024 VS 2031
 Figure 4. Eteplirsen Features
 Figure 5. Deflazacort Features
 Figure 6. Ataluren Features
 Figure 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application: 2024 VS 2031
 Figure 9. Hospitals Case Studies
 Figure 10. Clinics Case Studies
 Figure 11. Home Care Case Studies
 Figure 12. Drugs for Duchenne Muscular Dystrophy (DMD) Report Years Considered
 Figure 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region: 2024 VS 2031
 Figure 16. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Players in 2024
 Figure 17. Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2024
 Figure 19. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2020-2031)
 Figure 21. United States Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2020-2031)
 Figure 25. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2020-2031)
 Figure 33. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2020-2031)
 Figure 41. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2020-2031)
 Figure 45. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Sarepta Therapeutics Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
 Figure 49. PTC Therapeutics Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
 Figure 50. Pfizer Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
 Figure 51. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
 Figure 52. Italfarmaco Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
 Figure 53. Santhera Pharmaceuticals Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
 Figure 54. WaVe life Science Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2020-2025)
 Figure 55. Bottom-up and Top-down Approaches for This Report
 Figure 56. Data Triangulation
 Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Duchenne Muscular Dystrophy DMD Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Duchenne Muscular Dystrophy Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030
Myotonic Dystrophy Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Myotonic Dystrophy Drug Market Research Report 2024
Myotonic Dystrophy Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Myotonic Dystrophy Treatment Market Research Report 2025
Spinal Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Duchenne Muscular Dystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Spinal Muscular Atrophy SMA Treatment Market Research Report 2024
Global Amyotrophic Lateral Sclerosis Therapeutics Market Insights Forecast to 2030
Myotonic Muscular Dystrophy DMD Treatments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Musculoskeletal Disorders Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Amyotrophic Lateral Sclerosis ALS Treatment Market Insights Forecast to 2030
Global Drugs for Spinal Muscular Atrophy SMA Market Research Report 2024
Myasthenia Gravis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Amyotrophic Lateral Sclerosis ALS Market Insights Forecast to 2030
MSD Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Sarcopenia Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ophthalmology Disorders Drug Market Insights Forecast to 2030
Global Myasthenia Gravis Therapies Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions